Abstract: Objective: To evaluate the efficacy and safety of Xinmailong injection in the treatment of chronic heart failure(CHF).
Methods: The randomized controlled trial of Xinmailong injection in the treatment of CHF from the establishment of the database to
January 20, 2020 was searched in CNKI, VIP Chinese database, Wanfang database, PubMed, Cochrane Library and other databases.
Then, the appropriate literatures were selected, and the total clinical effective rate, left ventricular ejection fraction(LVEF), left ventricular
end diastolic diameter(LVEDD), 6 minutes walking distance(6MWD), N-terminal B-type brain natriuretic peptide(NT-proBNP), brain
natriuretic peptide(BNP) and the incidence of adverse reactions were Meta analyzed by Revman 5.3 software. Results: A total of 433
articles were retrieved, and finally fifteen RCTs with 1 996 CHF patients met the inclusion criteria and were included in the present
Meta-analysis. The results showed that the level of BNP，LVEDD, and NT-proBNP were significantly reduced and the LVEF, 6-MWD,
total clinical effective rate of CHF patients were significantly increased without causing obvious adverse reactions. Conclusion: In the
existing literature, Xinmailong injection can significantly improve the clinical indicators of CHF patients, improve the clinical efficacy,
and the incidence of adverse reactions is mild. However, the quality of literature is generally low, the information provided is insufficient,
and the source of literature bias is difficult to determine. Therefore, a large number of accurate and objective research is needed.

Key words: Xinmailong injection, chronic heart failure, Meta-analysis